Stubborn Support<br />By Rev Shark<br />RealMoney.com Contributor<br />9/1/2009 8:41 AM EDT <br /><br />It does not matter how slowly you go so long as you do not stop. <br />-- Confucius<br /><br />For a week now, market momentum has stalled out and the indices have gone nowhere. The bears see this as an indication that the furious uptrend since March is ready to stall out and the trend is about to turn down. That view is bolstered by the market's tepid response to recent good news. <br /><br />Given how far the market has moved in such a short period of time and our continuing economic challenges, it isn't hard to make a good argument for a market pullback. The only problem is that the market has simply paused so far and has not done anything other than churn a bit. Lack of upside progress isn't necessarily negative. It may simply be healthy consolidation that sets the stage for eventual further upside. <br /><br />Like many other market players, I've been rooting for the market to take a rest because there are so many extended charts that need time to set up and offer better entry points. Playing this market has been like jumping on a speeding train for a while, and some churning and consolidation would eventually help to produce some better trading. <br /><br />Over the past several months, the market has been unable to rest for very long because there have been so many underinvested bulls who have been anxious to do some buying on weakness. The irony of this very persistent underlying bid is that it has kept the market from resting for very long, which creates even more anxiety among the underinvested bulls. <br /><br />We're now faced with some big questions: Are these underinvested bulls who have been trying to jump in this market for so long finally going to relent? Are the dip-buyers going to become less supportive of the market and finally let a deeper correction occur? <br /><br />As the market has gone higher, many bulls capitulated and have paid up for stocks because they can't stand being left behind. That will reduce some of the underlying support for stocks, but lots of folks will be looking to jump in at some point, and if the market starts to strengthen once again, they are likely to buy on panic and squeeze the bears, who are finally becoming a bit more comfortable. <br /><br />The key to this market is the underlying support. Bears who think it is suddenly going to go away and that we will collapse are likely to have difficulty. A rollover in the market is going to be a process that slowly discourages the dip-buyers. It is only when they stop worrying about underperformance that the chances of a pullback will grow. <br /><br />We have some weakness this morning, but it feels like everyone is on vacation and that the market is extremely thin. The news flow is very slow, and there just isn't much going on. I'm particularly worried about a short squeeze in this sort of trading environment. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: EDAP +8.6% (light volume), CRMT +7.8%... Select biotech/swine flu vaccine related names showing strength: NVAX +14.2% (announces positive results for second Ph. II clinical trial of its trivalent seasonal influenza virus-like particle vaccine candidate), SVA +9.9% (Boryung Pharm to import Chinese-made H1N1 vaccine - Yonhap News Agency), VICL +7.4%, HEB +4.1%... Other news: YRCW +17.5% (discloses it entered into credit amendment), BEXP +10.4% (announces Figaro 29-32 #1H Bakken well produces at initial rate of ~1,895 BOEPD), OCLS +9.3% (continued strength following yesterday's 10% climb), ONCY +7.6% (light volume; has been granted its 32nd U.S. Patent entitled "Viruses for the Treatment of Cellular Proliferative Disorders"), HMPR +5.6% (continued momentum following yesterday's late jump on spike in volume), ICGN +4.2% (reports top line results of Phase IIa study of Senicapoc in allergic asthma), SPPI +3.1% (continued strength following yesterday's 10% pop), HSP +2.3% (receives FDA approval for six new presentations of Heparin), EBAY +2.1% (eBay is said to have deal to sell Skype - NY Times), PTR +1.6% (PetroChina in $1.7 bln Canadian project stake - Financial Times), BAC +1.3% (BofA seeks to repay a portion of bailout - WSJ)... Analyst comments: COH +3.4% (upgraded to Buy at BofA/Merrill), TXT +2.9% (light volume; upgraded to Overweight from Underweight at Morgan Stanley), HNT +2.5% (upgraded to Buy at Stifel Nicolaus), MEE +1.9% (upgraded to Buy at UBS), WLT +1.9% (upgraded to Buy at Merriman), RIMM +1.8% (upgraded to Outperform from Neutral at Credit Suisse), LMT +1.5% (upgraded to Buy at Citigroup), AMTD +1.2% (upgraded to Outperform from Market Perform at BMO Capital Markets ).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: CMED -11.7%, GMTN -4.6% (light volume)... Select financial names trading lower: AIG -7.3% (Maurice R. Greenberg and Howard I. Smith Agree to Binding Arbitration; also downgraded to Underperform at Bernstein), IRE -5.5%, AIB -4.9%, FRE -4.8%, CIT -2.9% (discloses it is not able to execute the APM and is required to defer interest on Notes), ABB -2.5%, MBI -2.5%, CS -2.3%, RBS -2.3%, HIG -2.2%, STD -2.1%, DB -1.8%, C -1.6%, BBV -1.5%, USB -1.4%, AZ -1.2%... Select metals/mining names showing weakness: GLG -1.8%, AU -2.9% (mixed securities shelf offering), GOLD -2.3%, MT -1.8%, RTP -1.6%... Other news: ACAD -64.9% (announces results from Ph. III trial of pimavanserin in Parkinson's disease psychosis; also downgraded to Sell from Hold at Citigroup), RMBS -11.0% (anti-trust trial delayed; BWS Financial says news is certainly going to be negative for RMBS shares this morning), BEAT -10.4% (announced that Highmark Medicare Services confirmed it will implement its reduced reimbursement rate for mobile cardiovascular technology on September 1, 2009), SQNM -8.5% (pulling back from yesterday's 15%+ surge higher), BLDR -8.3% (light volume; JLL Partners Fund and Warburg Pincus Private Equity propose recapitalization), GVP -7.9% (prices 2.5 mln common shares at $6.00/share), HCN -2.6% (announces a 5 mln share common stock offering), IMMU -1.8% (issues mixed securities offering, incl up to 20 mln shares of common stock and up to 3 mln in warrants)... Analyst comments: AXL -6.1% (downgraded to Hold at Deutsche Bank), PHG -3.5% (downgraded to Underperform from Neutral at Exane BNP Paribas), NOK -2.9% (downgraded to Underperform from Outperform at Credit Suisse), AET -1.1% (downgraded to Market Perform at Leerink Swann).